General Science

General Science Experts

Richard Pascoe

Chief Executive Officer
Apricus Biosciences
United States of America


 Richard W. Pascoe has been a director and served as our Chief Executive Officer since March 2013 and has served as the Company’s Secretary since February 2015. Mr. Pascoe joined the Company following the merger of Somaxon Pharmaceuticals, Inc. with Pernix Therapeutics Holdings, Inc. Mr. Pascoe was the Chief Executive Officer of Somaxon from August 2008 until joining the Company and was responsible for the FDA approval of Somaxon’s lead drug Silenor®. Prior to Somaxon, Mr. Pascoe was with ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company where he was most recently Senior Vice President and Chief Operating Officer. Prior to joining ARIAD in 2005, Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc. (acquired by Pfizer Inc.), including Senior Vice President positions in both marketing and sales, as well as Vice President positions in both international sales and marketing and hospital sales. Prior to King, Mr. Pascoe was in the commercial groups at Medco Research, Inc. (acquired by King), COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals Inc., the Takeda Oncology Company), B. Braun Interventional and The BOC Group. Mr. Pascoe is a member of the board of directors of KemPharm, Inc., as well as a member of the company’s audit and compensation committees and its lead independent director.  He also serves as a member of the board of directors of Biocom and the Johnny Mac Soldiers Fund, a charity for military veterans. Mr. Pascoe served as a Commissioned Officer with the U.S. Army 24th Infantry Division.  He is a graduate of the United States Military Academy at West Point where he received a B.S. degree in Leadership.

Research Interest


Global Experts from United States of America

Global Experts in Subject

Share This Profile